98%
921
2 minutes
20
N-linked glycosylation of flavivirus envelope proteins is widely viewed as being required for optimal folding, processing and/or transit of envelope proteins, and the assembling virons, through the endoplasmic reticulum (ER) and the Golgi. Zika virus (ZIKV) has a single N-linked envelope glycan located adjacent to the fusion loop. Herein we show that independent serial passage of ZIKV in mice for 223 or 386 days generated two unique envelope glycan-deficient mutants, ZIKV-V153D and ZIKV-N154D, respectively. Surprisingly, these mutants grew to titres ∼1 to 2.6 logs higher than the glycosylated parental ZIKV in Vero E6 cells and human brain organoids. RNA-Seq of infected organoids suggested that this increased replication fitness was associated with upregulation of the unfolded protein response (UPR). Cell death, cellular viral RNA, and viral protein levels were not significantly affected, arguing that these glycan mutants enjoyed faster ER/Golgi folding, processing, assembly, transit, and virion egress, assisted by an upregulated UPR. Thus, ZIKV envelope N-linked glycosylation is not essential for promoting envelope folding, assembly, and transit through the ER/Golgi, since aspartic acid (D) substitutions in the glycosylation motif can achieve this with significantly greater efficiency. Instead, the evolution of glycan mutants in mice indicates that such envelope glycosylation can have a fitness cost in an environment devoid of virus-specific antibody responses. The V153D and N154D mutations, generated by natural selection in mice, have to date not been employed in orthoflavivirus envelope glycosylation studies. Instead, genetic engineering has been used to generate mutant viruses that, for instance, contain a N154A substitution. The latter may impart confounding unfavourable properties, such as envelope protein insolubility, that have a detrimental impact on virus replication. The V153D and N154D substitutions may avoid imparting unfavourable properties by preserving the surface negative charge provided by the glycan moiety in the parental ZIKV envelope protein. In mice ZIKV-V153D and -N154D showed faster viremia onsets, but reduced viremic periods, than the parental ZIKV, consistent with an established contention that such glycans have evolved to delay neutralizing antibody activity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12024116 | PMC |
http://dx.doi.org/10.1093/ve/veaf021 | DOI Listing |
Vet Sci
July 2025
Provincial Key Laboratory of Animal, Molecular Design and Precise Breeding, School of Animal Science and Technology, Foshan University, Foshan 528225, China.
The Akabane virus (AKAV) is a significant member of the Orthobunyavirus genus, with its envelope glycoprotein Gc, focusing on its molecular structural features, immunoregulatory mechanisms, and application value in pathogen diagnosis and vaccine design. As a key structural protein of AKAV, Gc mediates virus adsorption and neutralizing antibody recognition through the N-terminal highly variable region (HVR), while the C-terminal conserved region (CR) dominates the membrane fusion process, and its glycosylation modification has a significant regulatory effect on protein function. In clinical diagnostics, serological assays based on Gc proteins (e.
View Article and Find Full Text PDFmSystems
August 2025
Ruth Rappaport Children's Hospital, Rambam Medical Center, Haifa, Israel.
is a major human pathogen, mostly infecting people with pre-existing lung conditions, such as cystic fibrosis. The production of glycopeptidolipids (GPL) is a major determinant of virulence of this bacterium, with clinical isolates that lack GPL generally exhibiting more aggressive clinical behavior. The current paradigm is that GPL production is abolished via irreversible, spontaneous mutations taking place as part of in-host evolution.
View Article and Find Full Text PDFJ Virol
August 2025
Department of Ecology & Evolutionary Biology, University of California Santa Cruz, Santa Cruz, California, USA.
The development of an effective vaccine against HIV-1 requires understanding how broadly neutralizing antibodies (bNAbs) evolve in natural viral infections. Here, we recovered 152 envelope sequences from two elite neutralizers (ENs) and five viral controllers and determined the neutralization sensitivity (IC) of each envelope glycoprotein (Env) to broadly neutralizing monoclonal antibodies (bN-mAbs). For the combined EN/controller data set, we observed that the median IC value for a CD4-binding site (CD4bs) bN-mAb (VRC01) was significantly lower for viruses lacking an N465 glycan.
View Article and Find Full Text PDFJ Virol
August 2025
Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
Enveloped virus surface antigens, such as influenza neuraminidase (NA), typically depend on linked glycans for assembly, trafficking in the host cell, and immune evasion. Here, we examined the function of the linked glycans on the NA stalk from H1N1 2009 pandemic (pdm09) viruses using reverse genetics coupled with a recombinant NA (rNA) analysis. Our results with the NA from A/Brisbane/02/2018 (H1N1) show that all five glycosylation sites in the stalk generally receive an linked glycan and that viral growth is largely unaffected by removing any of these sites individually.
View Article and Find Full Text PDFUnlabelled: Broadly neutralizing antibodies (bNAbs) provide a useful tool for HIV cure strategies because of their ability to target conserved regions on the envelope (Env) protein in the context of both virions and infected cells. One of the most well studied bNAbs is the CD4 binding site (CD4bs) antibody, VRC01 and others in its class. A major obstacle to effective cure strategies with bNAbs is viral immune escape.
View Article and Find Full Text PDF